What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Antibiotics/Anti-infectives

Exlla DS 100MG

Cefpodoxime 30ml Dry Syp(With Distilledwater)

Pack: 30ML
Format: With Carton

MRP₹84.38

A maximum-strength, third-generation cephalosporin antibacterial dry syrup designed for the intensive treatment of severe or resistant pediatric infections. EXLLA DS 100MG delivers a high-concentration dose of Cefpodoxime to provide rapid clinical recovery from acute respiratory, urinary, and skin infections in children.

About The Product

Key Benefits

Intensive Third-Generation Antibacterial Action

Cefpodoxime 100mg is a potent third-generation cephalosporin that works by inhibiting bacterial cell wall synthesis. Its broad-spectrum activity is highly effective against both Gram-positive and Gram-negative pathogens, offering a superior clinical success rate in treating infections that are resistant to standard penicillins.

Superior Stability and Resistance Management

EXLLA DS 100MG is naturally resistant to many beta-lactamase enzymes produced by bacteria. This ensures that the antibiotic remains active and potent where other medications might fail, making it a frontline choice for tough, recurrent, or deep-seated infections in the pediatric population.

Maximum Concentration for Severe Cases

The 100mg Double Strength formulation is specifically designed for cases requiring higher therapeutic levels of the antibiotic. This allows for a smaller volume of liquid to be administered per dose, which is critical for improving compliance in children who are fussy or have difficulty taking large amounts of medication.

Enhanced Bioavailability and Fast Recovery

The dry syrup is formulated for rapid absorption once reconstituted. By reaching peak plasma concentrations quickly, EXLLA DS 100MG ensures that the infection is brought under control rapidly, leading to a faster reduction in high-grade fever, pain, and inflammation.

Guaranteed Purity with Distilled Water

The inclusion of a 30ml Distilled Water pack ensures the highest level of safety and efficacy during reconstitution. Using pharmaceutical-grade distilled water prevents the introduction of minerals or impurities that could interfere with the stability and potency of the Cefpodoxime molecule.

Broad-Spectrum Clinical Utility

EXLLA DS 100MG is highly effective against major pediatric pathogens, including those responsible for pneumonia, severe ear infections, and complicated urinary tract infections. Its extended half-life allows for convenient twice-daily dosing, ensuring a steady bactericidal effect throughout the treatment course.

Indication Severe Acute Otitis Media, Community-Acquired Pneumonia, Acute Sinusitis and Tonsillitis, Complicated Urinary Tract Infections (UTIs), Skin and Soft Tissue Infections, Typhoid Fever (Enteric Fever).

Indications

Severe Acute Otitis Media
Community-Acquired Pneumonia
Acute Sinusitis and Tonsillitis
Complicated Urinary Tract Infections (UTIs)
Skin and Soft Tissue Infections
Typhoid Fever (Enteric Fever).

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

Exlla DS 100MG